Skin angiosarcoma

Summary

Skin angiosarcoma (MONDO:0003029) is a disease and 5 clinical trials. Top therapeutic interventions include cabozantinib. A subtype of skin sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin angiosarcoma
Mondo ID	MONDO:0003029
DOID	DOID:4517
NCIT	C4489
SNOMED CT	254794007
UMLS	C0346081
MedGen	87535
GARD	0023336
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	no

Also known as: angiosarcoma (disease) of zone of skin · angiosarcoma of skin · angiosarcoma of the skin · hemangiosarcoma of skin · hemangiosarcoma of the skin · skin angiosarcoma · skin hemangiosarcoma · zone of skin angiosarcoma (disease)

Data availability: 9 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm › dermis tumor › malignant dermis tumor › skin sarcoma › skin angiosarcoma

Related subtypes (4): cutaneous undifferentiated pleomorphic sarcoma, cutaneous leiomyosarcoma, cutaneous liposarcoma, skin lymphangiosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04339738	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
NCT06673628	PHASE2	RECRUITING	Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
NCT03544567	PHASE2	COMPLETED	A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
NCT03921073	PHASE2	TERMINATED	Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
NCT05729425	Not specified	TERMINATED	Evaluating the Accuracy of Microvessel Ultrasound Imaging for Detecting Extent of Disease in Patients With Angiosarcoma of the Skin

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3